Parexel CFO talks earnings, new business

By Melissa Fassbender

- Last updated on GMT

The complexity of clinical trials makes converting new business into revenue challenging. (Image: iStock/AndreyPopov)
The complexity of clinical trials makes converting new business into revenue challenging. (Image: iStock/AndreyPopov)

Related tags New business Revenue

Parexel has announced its financial results for the third quarter of FY16, which remained strong in spite of the complexities associated with smaller clinical trials.

The company performed well​,” Ingo Bank, Parexel's CFO, told Outsourcing-Pharma.com. “The quarter was one of our best ever for new business wins​.”

As a result of new business, the company’s book-to-bill ratio improved sequentially to 1.33, with gross new business reaching $999m. Additionally, service revenues were $527.1m, up 5.0%, compared to $502m in the prior year’s period.

Revenues meeting our expectations, led by our informatics and consulting businesses, and continued margin improvement drove diluted EPS growth of over 30% year over year​,” said Bank.

However, despite strong new business growth, Bank explained that the company is “seeing a lag in converting new business into revenue​.” 

According to Bank, the reason for this is that most of the company’s clinical trials are small and complex, which results in longer site initiation and start-up times, and challenges with patient accrual. 

We think this prolongation of trials will have reached steady state sometime in Fiscal Year 2017​,” added Bank. “At that point, revenue growth may begin to come more in line with recent backlog growth​.”

The company’s backlog, as of March 31, 2016, was $5.7bn, which is an increase of 9.1% year-over-year.

Our pipeline of new business opportunities to drive future backlog growth remains strong​,” said Bank, who added that to company expects to see continuing growth in biopharma R&D spending and outsourcing penetration. “We believe we are well-positioned​,” he said.

Our goal is to compete effectively with other biopharmaceutical services companies by continuing to build our leadership position in our core businesses and by investing in adjacent areas to serve more of our customers’ needs​.”

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars